Copyright Reports & Markets. All rights reserved.

Impact of COVID-19 Outbreak on Pulmonary Fibrosis Drug, Global Market Research Report 2020

Request for Sample of this report
Buy now

1 Pulmonary Fibrosis Drug Market Overview

  • 1.1 Product Overview and Scope of Pulmonary Fibrosis Drug
  • 1.2 Covid-19 Impact on Pulmonary Fibrosis Drug Segment by Type
    • 1.2.1 Global Pulmonary Fibrosis Drug Sales Growth Rate Comparison by Type (2021-2026)
    • 1.2.2 Pirfenidone
    • 1.2.3 Nintedanib
  • 1.3 Covid-19 Impact on Pulmonary Fibrosis Drug Segment by Application
    • 1.3.1 Pulmonary Fibrosis Drug Sales Comparison by Application: 2020 VS 2026
    • 1.3.2 Hospital
    • 1.3.3 Clinic
  • 1.4 Covid-19 Impact on Global Pulmonary Fibrosis Drug Market Size Estimates and Forecasts
    • 1.4.1 Global Pulmonary Fibrosis Drug Revenue 2015-2026
    • 1.4.2 Global Pulmonary Fibrosis Drug Sales 2015-2026
    • 1.4.3 Pulmonary Fibrosis Drug Market Size by Region: 2020 Versus 2026
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Pulmonary Fibrosis Drug Industry
  • 1.7 COVID-19 Impact: Pulmonary Fibrosis Drug Market Trends

2 Covid-19 Impact on Global Pulmonary Fibrosis Drug Market Competition by Manufacturers

  • 2.1 Global Pulmonary Fibrosis Drug Sales Market Share by Manufacturers (2015-2020)
  • 2.2 Global Pulmonary Fibrosis Drug Revenue Share by Manufacturers (2015-2020)
  • 2.3 Global Pulmonary Fibrosis Drug Average Price by Manufacturers (2015-2020)
  • 2.4 Manufacturers Pulmonary Fibrosis Drug Manufacturing Sites, Area Served, Product Type
  • 2.5 Pulmonary Fibrosis Drug Market Competitive Situation and Trends
    • 2.5.1 Pulmonary Fibrosis Drug Market Concentration Rate
    • 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
    • 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
  • 2.7 Primary Interviews with Key Pulmonary Fibrosis Drug Players (Opinion Leaders)

3 Covid-19 Impact on Pulmonary Fibrosis Drug Retrospective Market Scenario by Region

  • 3.1 Global Pulmonary Fibrosis Drug Retrospective Market Scenario in Sales by Region: 2015-2020
  • 3.2 Global Pulmonary Fibrosis Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
  • 3.3 North America Pulmonary Fibrosis Drug Market Facts & Figures by Country
    • 3.3.1 North America Pulmonary Fibrosis Drug Sales by Country
    • 3.3.2 North America Pulmonary Fibrosis Drug Sales by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe Pulmonary Fibrosis Drug Market Facts & Figures by Country
    • 3.4.1 Europe Pulmonary Fibrosis Drug Sales by Country
    • 3.4.2 Europe Pulmonary Fibrosis Drug Sales by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Pulmonary Fibrosis Drug Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Pulmonary Fibrosis Drug Sales by Region
    • 3.5.2 Asia Pacific Pulmonary Fibrosis Drug Sales by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America Pulmonary Fibrosis Drug Market Facts & Figures by Country
    • 3.6.1 Latin America Pulmonary Fibrosis Drug Sales by Country
    • 3.6.2 Latin America Pulmonary Fibrosis Drug Sales by Country
    • 3.6.3 Mexico
    • 3.6.3 Brazil
    • 3.6.3 Argentina
  • 3.7 Middle East and Africa Pulmonary Fibrosis Drug Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Pulmonary Fibrosis Drug Sales by Country
    • 3.7.2 Middle East and Africa Pulmonary Fibrosis Drug Sales by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 U.A.E

4 Covid-19 Impact on Global Pulmonary Fibrosis Drug Historic Market Analysis by Type

  • 4.1 Global Pulmonary Fibrosis Drug Sales Market Share by Type (2015-2020)
  • 4.2 Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2015-2020)
  • 4.3 Global Pulmonary Fibrosis Drug Price Market Share by Type (2015-2020)
  • 4.4 Global Pulmonary Fibrosis Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Covid-19 Impact on Global Pulmonary Fibrosis Drug Historic Market Analysis by Application

  • 5.1 Global Pulmonary Fibrosis Drug Sales Market Share by Application (2015-2020)
  • 5.2 Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2015-2020)
  • 5.3 Global Pulmonary Fibrosis Drug Price by Application (2015-2020)

6 Company Profiles and Key Figures in Pulmonary Fibrosis Drug Business

  • 6.1 Boehringer Ingelheim
    • 6.1.1 Corporation Information
    • 6.1.2 Boehringer Ingelheim Description, Business Overview and Total Revenue
    • 6.1.3 Boehringer Ingelheim Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
    • 6.1.4 Boehringer Ingelheim Products Offered
    • 6.1.5 Boehringer Ingelheim Recent Development and Response to COVID-19
  • 6.2 Roche
    • 6.2.1 Roche Corporation Information
    • 6.2.2 Roche Description, Business Overview and Total Revenue
    • 6.2.3 Roche Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
    • 6.2.4 Roche Products Offered
    • 6.2.5 Roche Recent Development and Response to COVID-19
  • 6.3 FibroGen, Inc.
    • 6.3.1 FibroGen, Inc. Corporation Information
    • 6.3.2 FibroGen, Inc. Description, Business Overview and Total Revenue
    • 6.3.3 FibroGen, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
    • 6.3.4 FibroGen, Inc. Products Offered
    • 6.3.5 FibroGen, Inc. Recent Development and Response to COVID-19
  • 6.4 Merck & Co., Inc.
    • 6.4.1 Merck & Co., Inc. Corporation Information
    • 6.4.2 Merck & Co., Inc. Description, Business Overview and Total Revenue
    • 6.4.3 Merck & Co., Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
    • 6.4.4 Merck & Co., Inc. Products Offered
    • 6.4.5 Merck & Co., Inc. Recent Development and Response to COVID-19
  • 6.5 Bristol-Myers Squibb Company
    • 6.5.1 Bristol-Myers Squibb Company Corporation Information
    • 6.5.2 Bristol-Myers Squibb Company Description, Business Overview and Total Revenue
    • 6.5.3 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
    • 6.5.4 Bristol-Myers Squibb Company Products Offered
    • 6.5.5 Bristol-Myers Squibb Company Recent Development and Response to COVID-19
  • 6.6 MediciNova, Inc.
    • 6.6.1 MediciNova, Inc. Corporation Information
    • 6.6.2 MediciNova, Inc. Description, Business Overview and Total Revenue
    • 6.6.3 MediciNova, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
    • 6.6.4 MediciNova, Inc. Products Offered
    • 6.6.5 MediciNova, Inc. Recent Development and Response to COVID-19
  • 6.7 Genentech, Inc.
    • 6.6.1 Genentech, Inc. Corporation Information
    • 6.6.2 Genentech, Inc. Description, Business Overview and Total Revenue
    • 6.6.3 Genentech, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
    • 6.4.4 Genentech, Inc. Products Offered
    • 6.7.5 Genentech, Inc. Recent Development and Response to COVID-19
  • 6.8 Cipla Inc.
    • 6.8.1 Cipla Inc. Corporation Information
    • 6.8.2 Cipla Inc. Description, Business Overview and Total Revenue
    • 6.8.3 Cipla Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
    • 6.8.4 Cipla Inc. Products Offered
    • 6.8.5 Cipla Inc. Recent Development and Response to COVID-19
  • 6.9 Biogen
    • 6.9.1 Biogen Corporation Information
    • 6.9.2 Biogen Description, Business Overview and Total Revenue
    • 6.9.3 Biogen Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
    • 6.9.4 Biogen Products Offered
    • 6.9.5 Biogen Recent Development and Response to COVID-19
  • 6.10 Galapagos NV
    • 6.10.1 Galapagos NV Corporation Information
    • 6.10.2 Galapagos NV Description, Business Overview and Total Revenue
    • 6.10.3 Galapagos NV Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
    • 6.10.4 Galapagos NV Products Offered
    • 6.10.5 Galapagos NV Recent Development and Response to COVID-19

7 Pulmonary Fibrosis Drug Manufacturing Cost Analysis

  • 7.1 Pulmonary Fibrosis Drug Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Raw Materials Price Trend
    • 7.1.3 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Pulmonary Fibrosis Drug
  • 7.4 Pulmonary Fibrosis Drug Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Pulmonary Fibrosis Drug Distributors List
  • 8.3 Pulmonary Fibrosis Drug Customers

9 Market Dynamics

  • 9.1 Market Trends
  • 9.2 Opportunities and Drivers
  • 9.3 Challenges
  • 9.4 Porter's Five Forces Analysis

10 Global Market Forecast

  • 10.1 Global Pulmonary Fibrosis Drug Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Pulmonary Fibrosis Drug by Type (2021-2026)
    • 10.1.2 Global Forecasted Revenue of Pulmonary Fibrosis Drug by Type (2021-2026)
  • 10.2 Pulmonary Fibrosis Drug Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Pulmonary Fibrosis Drug by Application (2021-2026)
    • 10.2.2 Global Forecasted Revenue of Pulmonary Fibrosis Drug by Application (2021-2026)
  • 10.3 Pulmonary Fibrosis Drug Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Pulmonary Fibrosis Drug by Region (2021-2026)
    • 10.3.2 Global Forecasted Revenue of Pulmonary Fibrosis Drug by Region (2021-2026)
  • 10.4 North America Pulmonary Fibrosis Drug Estimates and Projections (2021-2026)
  • 10.5 Europe Pulmonary Fibrosis Drug Estimates and Projections (2021-2026)
  • 10.6 Asia Pacific Pulmonary Fibrosis Drug Estimates and Projections (2021-2026)
  • 10.7 Latin America Pulmonary Fibrosis Drug Estimates and Projections (2021-2026)
  • 10.8 Middle East and Africa Pulmonary Fibrosis Drug Estimates and Projections (2021-2026)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
    Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Pulmonary Fibrosis Drug market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
    This report also analyzes the impact of Coronavirus COVID-19 on the Pulmonary Fibrosis Drug industry.

    Segment by Type, the Pulmonary Fibrosis Drug market is segmented into
    Pirfenidone
    Nintedanib

    Segment by Application
    Hospital
    Clinic

    Global Pulmonary Fibrosis Drug Market: Regional Analysis
    The Pulmonary Fibrosis Drug market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
    The key regions covered in the Pulmonary Fibrosis Drug market report are:
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    U.A.E

    Global Pulmonary Fibrosis Drug Market: Competitive Analysis
    This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

    The major players in global Pulmonary Fibrosis Drug market include:
    Boehringer Ingelheim
    Roche
    FibroGen, Inc.
    Merck & Co., Inc.
    Bristol-Myers Squibb Company
    MediciNova, Inc.
    Genentech, Inc.
    Cipla Inc.
    Biogen
    Galapagos NV
    Buy now